Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1075 | 1050 | 1182 | 1093 | 1470 | 1560 |
Fund Return | 7.51% | 4.97% | 18.22% | 3.01% | 8.01% | 4.55% |
Place in category | 338 | 446 | 275 | 145 | 266 | 175 |
% in Category | 42 | 54 | 40 | 26 | 41 | 47 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
American Funds NVIT Asset Allocatio | 6.47B | 6.37 | 3.14 | 7.26 | ||
NVIT SP 500 Index Fund Class II | 2.4B | 11.06 | 9.04 | 12.15 | ||
American Funds NVIT Growth Fund II | 1.79B | 11.29 | 6.26 | 14.89 | ||
NVIT Investor Destinations Balance2 | 1.15B | 3.44 | 0.80 | 4.47 | ||
Nationwide Institutional Service | 1.14B | 11.35 | 8.23 | 11.76 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Intl Stock Index Inv | 197.89B | 6.01 | 0.42 | 4.22 | ||
Vanguard Total Intl Stock Index Adm | 75.61B | 6.04 | 0.47 | 4.29 | ||
Fidelity International Index Inst | 50.5B | 7.74 | 3.30 | 4.80 | ||
Fidelity Series Global ex US Index | 45.8B | 6.35 | 0.53 | 4.10 | ||
Vanguard Total Intl Stock Index I | 41.01B | 6.06 | 0.50 | 4.32 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 2.55 | 993.5 | -1.10% | |
ASML Holding | NL0010273215 | 2.23 | 965.90 | +1.22% | |
Nestle | CH0038863350 | 1.70 | 92.52 | +0.70% | |
AstraZeneca | GB0009895292 | 1.39 | 12,086.0 | -1.77% | |
Shell | GB00BP6MXD84 | 1.37 | 34.06 | +0.52% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Strong Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Neutral | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review